Phase 2 study of alternate-day administrations of S-1 in elderly patients with advanced/recurrent gastric cancer (KDOG 1301)
- Conditions
- Advanced or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000013019
- Lead Sponsor
- Department of Gastroenterology, Kitasato University School of Medicine
- Brief Summary
Clinical trial discontinued due to sluggish accumulation of 6 registered cases
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
1. History of hypersensitivity for S-1 or ingredients of S-1 2. Patient who takes flucytosine, or phenytoin 3. Severe bone marrow suppression, severe renal dysfunction, or severe liver dysfunction 4. Severe concomitant disease (congestive heart failure, hemorrhagic peptic ulcer, ileus, symptomatic ischemic heart disease, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema or etc) 5. Patient who suffered from myocardial infarction or cerebral infarction within six months 6. symptomatic brain metastasis 7. Severe mental disorders 8. Active synchronous malignancy 9. Watery diarrhea 10. HBV carrier who has to take nucleotide analogues (e.g. Entecavir) during chemotherapy 11. Patient who is judged inappropriate for the entry into this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method